Transcatheter arterial chemoembolization （TACE） is the standard treatment for Barcelona Clinic Liver Cancer （BCLC） stage B hepatocellular carcinoma （HCC）. However, TACE has some limitations, TACE combined with systemic therapy may be more beneficial to patients with BCLC stage B/C HCC. To explore the efficacy and safety of TACE combined with molecular targeted therapy, immunotherapy and molecular targeted therapy + immunotherapy in the treatment of B/C stage HCC of BCLC will provide new ideas for the clinical treatment of HCC.